RxDoctor Payments Data

Philippe Lam, MD

Internal Medicine · Las Vegas, NVNPI 1417243684

Payments from drug & device makers

$1,456in general payments, 2019–2025

Across 29 payments — averaging $50.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Encore Medical, LP$962
  • Exact Sciences$133
  • Lilly USA, LLC$79
  • Johnson & Johnson$70
  • GSK$49
  • AstraZeneca$31
  • plus $133 from 6 others

What the payments were for

  • Travel & lodging$96266%
  • Food & beverage$43030%
  • Education$644%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,456 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$9,225
Medicare patients
30
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$126,994
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen134$125,575
TrulicityDulaglutide49$106,777
RybelsusSemaglutide45$103,692
FarxigaDapagliflozin Propanediol42$64,810
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$45,256
XareltoRivaroxaban31$41,593
MounjaroTirzepatide28$39,279
OzempicSemaglutide16$29,897
VemlidyTenofovir Alafenamide19$29,787
JardianceEmpagliflozin17$28,544
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$20,577
Breo ElliptaFluticasone/Vilanterol17$9,485
SymbicortBudesonide/Formoterol Fumarate12$7,728
Atorvastatin Calcium1,048$7,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$79$146,05677 claims
Novo NordiskRybelsus, Ozempic$15$133,58961 claims
PfizerEliquis$18$126,99472 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$31$93,11471 claims
GSKTrelegy Ellipta, Breo Ellipta$49$54,74051 claims
Johnson & JohnsonXarelto$70$41,59331 claims
Boehringer IngelheimJardiance$26$28,54417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →